Status:
COMPLETED
The Role of KL-6 in the Clinical Diagnosis of ILD
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Collaborating Sponsors:
Fujirebio Diagnostics, Inc.
Conditions:
Interstitial Lung Disease
Eligibility:
All Genders
14-90 years
Brief Summary
The purpose of the study is to evaluate the significance of KL-6 as a biomarker in the clinical diagnosis of interstitial lung disease (ILD) by detecting serum KL-6 levels among patients with ILD, and...
Detailed Description
As a multi-center, double-blind clinical study, the trial is divided into two parts. Part 1: The purpose of this part is to evaluate the role of KL-6 as a biomarker in the clinical diagnosis of inter...
Eligibility Criteria
Inclusion
- Serums from patients with ILD, pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease and health
- Serums from patients with ILD: before treatment and 30-90 days after treatment
Exclusion
- Serums from patients with cancer
- Serums with visible precipitate
- Serums with floc
Key Trial Info
Start Date :
December 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
1190 Patients enrolled
Trial Details
Trial ID
NCT02197364
Start Date
December 1 2013
End Date
May 1 2014
Last Update
July 22 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.